Cartesian Therapeutics (RNAC) Notes Payables (2023)

Cartesian Therapeutics' (RNAC) quarterly Notes Payables came in at $28.3 million in Q4 2023.

Cartesian Therapeutics (RNAC) Notes Payables (2023) Analysis & Trends

Cartesian Therapeutics (RNAC) has 1 years of Notes Payables data on file, last reported at $28.3 million in Q4 2023.

On a quarterly basis, Notes Payables changed N/A year-over-year to $28.3 million in Q4 2023; TTM through Dec 2023 was $28.3 million, a N/A change from a year earlier, with the FY2023 full-year figure at $28.3 million, changed N/A from the prior year.
Notes Payables for Q4 2023 stood at $28.3 million.
Over the last five years, Notes Payables for RNAC reached as high as $28.3 million in Q4 2023 and fell as low as $28.3 million in Q4 2023.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Cartesian Therapeutics	226.07 Mn	226.07 Mn	-

Historic Data

Download Data

Date	Value
Dec 31, 2023	28.31 Mn